Tag Archives: biotechnology

Ariad: “The Future Ain’t What It Used To Be!” Judge Linn’s Concurrence and the Abuse and Neglect of the Enablement Requirement at the Federal Circuit

Posted on May 5, 2009 by Warren Woessner

In my post of April 13, 2009, I concluded with a brief summary of Judge Linn’s cogent concurrence, and noted that I would revisit it. Judge Linn does not believe that it was ever necessary for the court to graft … Continue reading →

Posted in Written Description Requirements (WDR) | Tagged , , , , , , , , , | Leave a comment

Patent Office Bats Down Ariad’s ‘Hail Mary Claims’ In Reexamination

Posted on April 22, 2009 by Warren Woessner

In my earlier post on Ariad v Lilly, there is a detailed discussion of the Federal Circuit’s recent decision that invalidated all of the claims-in-suit for failure to meet the written description requirement. The Federal Circuit rejected Lilly’s attempts to … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , | Leave a comment

In Search of University Patents

Posted on April 20, 2009 by Warren Woessner

Technology Transfer Tactics, in conjunction with FreePatentsOnline, has created a site (link below) which they state can allow the visitor to view all of a given university’s patents by just clicking on the name of the institution. However, while this … Continue reading →

Posted in Tech Transfer | Tagged , , , , , , , | Leave a comment

Federal Circuit Throws a Wrench into “Mechanism of Action” Claims

Posted on April 13, 2009 by Warren Woessner

A three-judge panel of the Court of Appeals for the Federal Circuit recently decided Ariad Pharmaceuticals, Inc. et al. v. Eli Lilly & Company, appeal no. 2008-1248 (Fed. Cir. April 3, 2009), involving Blatimore et al. (U.S. Pat. No. 6,410,516). … Continue reading →

Posted in Written Description Requirements (WDR) | Tagged , , , , , , , , , , , , | Leave a comment